MY122499A - Use of alkylated iminosugars to treat multidrug resistance - Google Patents

Use of alkylated iminosugars to treat multidrug resistance

Info

Publication number
MY122499A
MY122499A MYPI98005087A MYPI9805087A MY122499A MY 122499 A MY122499 A MY 122499A MY PI98005087 A MYPI98005087 A MY PI98005087A MY PI9805087 A MYPI9805087 A MY PI9805087A MY 122499 A MY122499 A MY 122499A
Authority
MY
Malaysia
Prior art keywords
multidrug resistance
iminosugars
treat multidrug
relates
present
Prior art date
Application number
MYPI98005087A
Other languages
English (en)
Inventor
Gary S Jacob
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of MY122499A publication Critical patent/MY122499A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
MYPI98005087A 1997-11-10 1998-11-09 Use of alkylated iminosugars to treat multidrug resistance MY122499A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6505197P 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
MY122499A true MY122499A (en) 2006-04-29

Family

ID=22060028

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98005087A MY122499A (en) 1997-11-10 1998-11-09 Use of alkylated iminosugars to treat multidrug resistance

Country Status (15)

Country Link
US (1) US6225325B1 (enExample)
EP (1) EP1030839B1 (enExample)
JP (1) JP2001522833A (enExample)
AR (1) AR018732A1 (enExample)
AT (1) ATE258919T1 (enExample)
AU (1) AU753336B2 (enExample)
CA (1) CA2309321A1 (enExample)
DE (1) DE69821520T2 (enExample)
DK (1) DK1030839T3 (enExample)
ES (1) ES2216327T3 (enExample)
MY (1) MY122499A (enExample)
PT (1) PT1030839E (enExample)
TW (1) TW581677B (enExample)
WO (1) WO1999024401A1 (enExample)
ZA (1) ZA9810210B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761748B2 (en) 1997-12-11 2003-06-12 Chancellor, Masters And Scholars Of The University Of Oxford, The Inhibition of membrane-associated viral replication
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000056334A1 (en) * 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
DE60037664T2 (de) 1999-08-10 2008-12-24 The Chancellor, Masters And Scholars Of The University Of Oxford Langkettige n-alkyl verbindungen und deren oxa-derivate zur verwendung als anitvirale mittel
GB0006539D0 (en) * 2000-03-17 2000-05-10 Oxford Glycosciences Uk Ltd Therapies
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
CA2465886A1 (en) * 2001-11-07 2003-05-15 Kathleen S. Crowley Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003248960B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
ES2393331T3 (es) 2002-07-17 2012-12-20 Actelion Pharmaceuticals Ltd. Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ES2581184T3 (es) * 2003-01-31 2016-09-01 Childrens Hospital Los Angeles Composiciones orales de fenretinida que tienen mayor biodisponibilidad y métodos de uso de las mismas
AU2003206021A1 (en) * 2003-02-20 2004-09-09 Ranbaxy Laboratories Limited Derivatives of azasugars as anticancer agents
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
WO2005123055A2 (en) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
CN101489554A (zh) 2006-05-24 2009-07-22 联合治疗公司 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
CN102727437A (zh) 2006-08-02 2012-10-17 牛津大学院长校长专家委员会 病毒感染的脂质体治疗
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
EP2410989A2 (en) 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
WO2014143999A1 (en) * 2013-03-15 2014-09-18 Unither Virology, Llc Antibacterial compounds
JP6851964B2 (ja) 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
US12612380B2 (en) 2019-05-10 2026-04-28 Alectos Therapeutics 1Nc Non-lysosomal glucosylceramidase inhibitors and uses thereof
PE20231423A1 (es) 2020-05-07 2023-09-13 Alectos Therapeutics Inc Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
JP7674389B2 (ja) * 2020-05-07 2025-05-09 アレクトス セラピューティックス インコーポレイテッド 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
WO2023187051A1 (en) * 2022-03-30 2023-10-05 Basf Se Process for the production of a tertiary amine surfactant
WO2025017212A1 (en) * 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Udp-glucose ceramide glucosyltransferase synthase (ugcg) inhibitors in the treatment of cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US452406A (en) 1891-05-19 Hanger for pictures
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3049446A1 (de) 1980-12-30 1982-07-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,5-didesoxy-1,5-imino-d-glucitol und dessen n-derivaten
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
WO1987003903A1 (en) 1985-12-23 1987-07-02 Fred Hutchinson Cancer Research Center Regulating retroviral replication, infection, and pathogenesis
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
JPH01203326A (ja) * 1987-12-21 1989-08-16 Monsanto Co ヒト免疫不全ウイルス抑制剤
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
FI101344B (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
EP0350012A3 (en) 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
US5144037A (en) * 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US5003072A (en) 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5310745A (en) 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US4957926A (en) 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
DE4009561A1 (de) 1990-03-24 1991-09-26 Bayer Ag Neue desoxynojirimycinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5536732A (en) * 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
US5151519A (en) 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
DK0477160T3 (da) 1990-09-20 1996-05-20 Monsanto Co Fremgangsmåde til fremstilling af N-substitueret 1-deoxynojirimycin
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
IL105090A (en) 1992-03-18 1998-08-16 Us Bioscience Acid N) phosphonoacetyl (Aspartic L in a broad spectrum antiviral agent
US5258518A (en) * 1992-04-01 1993-11-02 G. D. Searle & Co. 2-substituted tertiary carbinol derivatives of deoxynojirimycin
US5331096A (en) 1992-04-01 1994-07-19 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
WO1994004546A1 (fr) 1992-08-14 1994-03-03 Nippon Shinyaku Co., Ltd. Derive de moranoline
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
AU7518694A (en) 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
DK0739205T3 (da) 1994-01-13 2000-05-01 Searle & Co Anvendelse af N-alkylderivater af 1,5-didesoxy-1,5-imino-D-glucitol til behandling af hepatitis-B-virusinfektioner
AU1876095A (en) * 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
WO1997000881A1 (fr) 1995-06-22 1997-01-09 Nippon Shinyaku Co., Ltd. Derives de la moranoline
ES2244048T3 (es) 1997-02-14 2005-12-01 G.D. Searle Llc. Uso de compuestos (n)-sustituidos-1,5-didesoxi-1,5-imino-d-glucitol en terapia de combinacion para el tratamiento de infecciones con virus de hepatitis.

Also Published As

Publication number Publication date
AR018732A1 (es) 2001-12-12
ES2216327T3 (es) 2004-10-16
JP2001522833A (ja) 2001-11-20
WO1999024401A1 (en) 1999-05-20
ATE258919T1 (de) 2004-02-15
CA2309321A1 (en) 1999-05-20
TW581677B (en) 2004-04-01
ZA9810210B (en) 1999-07-14
EP1030839B1 (en) 2004-02-04
DE69821520D1 (de) 2004-03-11
DE69821520T2 (de) 2004-12-16
DK1030839T3 (da) 2004-05-03
AU1297399A (en) 1999-05-31
EP1030839A1 (en) 2000-08-30
US6225325B1 (en) 2001-05-01
AU753336B2 (en) 2002-10-17
PT1030839E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
AU747599C (en) Antitumor agents
IL103622A (en) Heteroarylpiperidines pyrrolidines and piperazines and antipsychotic and analgetic pharmaceutical compositions containing them
MY132073A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
DE69811329D1 (de) Imidazolidin-4-on Derivate verwendbar als Antikrebsmittel
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
WO2002036135A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
WO1993007866A3 (en) Compositions and methods for therapy and prevention of cancer, aids, and anemia
IL137964A0 (en) Antitumor agents
GR3025207T3 (en) 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents
WO2002007678A3 (en) Mu-conopeptides
GR3031114T3 (en) Use of a pregnane derivatives for the treatment of tumours.
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
YU46302A (sh) Supstituisani piroli
NO902528L (no) Substituerte aminoalkylbenzenderivater.
DE69430356D1 (de) Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
DK495285D0 (da) Spiro-heteroazolon-forbindelser og farmaceutiske praeparater
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
RU95107154A (ru) Производные 5,6-дигидро-4н-тиено[3,4-c]пиррола, их получение и содержащие их медикамент и фармацевтическая композиция